Ei.Ventures Announce Engagement With Tioga Research to Develop Transdermal Patch for Psilocin Delivery

Ei.Ventures Announce Engagement With Tioga Research to Develop Transdermal Patch for Psilocin Delivery

Ei.Ventures Announce Engagement With Tioga Research to Develop Transdermal Patch for Psilocin Delivery

MAUI, Hawaii & SAN DIEGO–(BUSINESS WIRE)–Noted psychedelic medicine start-up Ei.Ventures is excited to announce their engagement with Tioga Research to develop a transdermal patch for sustained delivery of psilocin, the active ingredient in psilocybin mushrooms, for mental health applications.

David Nikzad, the CEO of Ei.Ventures notes, “we are over the moon to join with one of the top transdermal delivery research specialists, Tioga Research, to begin developing products that could potentially help millions of people manage their mental health issues – depression, anxiety, PTSD, etc. with a patch. Additionally, with the increasing legality and popularity of psilocybin mushrooms, transdermal delivery could become a popular method for micro-dosing which helps with mental clarity and mood stabilization as well.”

John M. Newsam, CEO of Tioga Research adds, “By working with Ei.Ventures on a blue sky project of this nature, we will deploy our proprietary technologies and deep expertise to address key psilocin formulation issues, such as delivery and stability. A transdermal delivery route can circumvent issues with oral administration, such as nausea.”

EI.Ventures is focused on developing botanical active pharmaceutical ingredients for the psychedelic supply chain, novel psychedelic compounds for various indications, and unique delivery mechanisms and treatment protocols. In addition to their future regulated psychedelic line, Ei.Ventures will release their MANA range of functional mushroom nutraceuticals for improving well-being and health in Q3 2021.

Tioga Research supports the research and early development of skin-applied products, offering formulation innovation, skin permeation screening, and GLP IVRT/IVPT services. In addition, the company has pioneered high throughput experimentation (“HTE”) technologies for screening skin delivery. Tioga Research was founded in 2011 to support innovations in skin-applied products, especially topical and transdermal drug products, including skincare products and cosmetics. With headquarters and laboratory operations in San Diego, CA, and a business presence in the UK to support clients in Europe, Tioga Research has become a preferred service provider for an impressive portfolio of clients across the Americas, Europe, and Asia. Tioga Research has been a subsidiary of Encube Ethicals since early 2020, enabling clients to leverage the combined strengths of both organizations from early formulation innovation to commercial manufacturing.

For more information on Ei.Ventures, please go to https://invest.ei.ventures/. For media needs, please contact Susan von Seggern at susan@susanvonseggern.com or 213-840-0077.

Forward Looking Statements: Certain information set forth in this presentation, together with any supplements and any other information that may be furnished to prospective investors by the Company in connection therewith, contains “forward-looking statements” and “forward-looking information” within the meaning of applicable United States securities legislation (referred to herein as forward-looking statements). Except for statements of historical fact, certain information contained herein constitutes forward-looking statements which include but are not limited to statements related to activities, events or developments that Ei.Ventures expects or anticipates will or may occur in the future, statements related to the Company’s business strategy objectives and goals, and management’s assessment of future plans and operations which are based on current internal expectations, estimates, projections ,assumptions and beliefs, which may prove to be incorrect. Forward-looking statements can often be identified by the use of words such as “may”, “will”, “could”, “would”, “anticipate”, ‘believe”, expect”, “intend”, “potential”, “estimate”, “budget”, “scheduled”, “plans”, “planned”, “forecasts”, “goals” and similar expressions or the negatives thereof. Forward-looking statements are neither historical facts nor assurances of future performance. Forward-looking statements are based on a number of factors and assumptions made by management and considered reasonable at the time such information is provided, and forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements.


Susan von Seggern